Clearmind Medicine Files International Patent for MDMA-Based Alcohol Treatment
Ticker: CMND · Form: 6-K · Filed: Sep 6, 2024 · CIK: 1892500
Sentiment: bullish
Topics: patent, pharmaceutical, mental-health, drug-development
TL;DR
Clearmind files international patent for MDMA + naltrexone combo to treat alcohol addiction. Big deal for mental health tech.
AI Summary
Clearmind Medicine Inc. announced on September 6, 2024, the publication of an international patent application for a novel combination treatment utilizing MDMA. This patent application covers a method for treating alcohol use disorder by administering a combination of MDMA and an opioid antagonist, such as naltrexone. The company believes this innovative approach could offer a significant advancement in the treatment of alcohol addiction.
Why It Matters
This patent filing could protect Clearmind Medicine's intellectual property for a potentially groundbreaking treatment for alcohol use disorder, impacting the future of addiction therapy.
Risk Assessment
Risk Level: medium — The company is in the early stages of patent application and clinical development, with significant regulatory and market risks associated with novel drug therapies.
Key Players & Entities
- Clearmind Medicine Inc. (company) — Filer of the 6-K report and applicant of the patent
- MDMA (drug) — Key component of the patented treatment
- naltrexone (drug) — Opioid antagonist used in combination with MDMA
- September 6, 2024 (date) — Date of the press release and patent application publication
FAQ
What is the specific title of the press release incorporated into this 6-K filing?
The press release is titled "Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment".
What is the primary focus of the international patent application filed by Clearmind Medicine?
The patent application focuses on a method for treating alcohol use disorder by administering a combination of MDMA and an opioid antagonist, such as naltrexone.
On what date was the press release announcing the patent application published?
The press release was published on September 6, 2024.
What is Clearmind Medicine Inc.'s Central Index Key (CIK) number?
Clearmind Medicine Inc.'s Central Index Key (CIK) number is 0001892500.
Which form does Clearmind Medicine Inc. indicate it files annual reports under?
Clearmind Medicine Inc. indicates it files annual reports under Form 20-F.
Filing Stats: 267 words · 1 min read · ~1 pages · Grade level 13.9 · Accepted 2024-09-06 16:01:30
Filing Documents
- ea0213753-6k_clearmind.htm (6-K) — 12KB
- ea021375302ex99-1_clearmind.htm (EX-99.1) — 12KB
- ex99-1_001.jpg (GRAPHIC) — 2KB
- 0001213900-24-076503.txt ( ) — 27KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Clearmind Medicine, Inc. (Registrant) Date: September 6, 2024 By: /s/ Adi Zuloff-Shani Name: Adi Zuloff-Shani Title: Chief Executive Officer 3